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Effect of erythropoietin therapy and withdrawal on blood coagulation
and fibrinolysis in hemodialysis patients. Erythropoietin (EPO) therapy
in hemodialysis patients may be associated with an enhanced risk of
vascular access and extracorporeal thrombosis. Assessment of blood
coagulation and fibrinolysis was performed monthly on a group of 21
hemodialysis patients treated with EPO, and on four iron-deficient
hemodialysis patients treated with iron dextran infusions alone. Seven-
teen of the EPO treated patients were also monitored after withdrawal
of EPO to allow hemoglobin to fall to pre-EPO levels, and 16 of these
patients during a second subsequent phase of EPO therapy with EPO
administered using the alternative roUte (subcutaneous/intravenous)
from the first phase of treatment. Ten untreated hemodialysis patients
with intrinsically high hemoglobins were studied as controls. EPO was
associated with significant increases in the endothelial product Factor
VIII von Willebrand factor antigen (FVIIIvWFAg), and plasma fibrin-
ogen, to levels comparable to those observed in the untreated control
patients. Both FVIIIvWFAg and fibrinogen remained significantly
elevated when EPO was withdrawn. Whole blood platelet aggregation
(spontaneous, collagen, and ADP-induced) also increased following
EPO, collagen and ADP-induced aggregation, increasing further when
EPO was withdrawn. Transient but significant changes occurred in
plasma measures of thrombin-antithrombin III complex, prostacycin
stimulating factor, and protein C during the first EPO treatment phase,
and also thrombin-antithrombin III complex during the second treat-
ment phase, all favoring a tendency to thrombosis. D-dimer increased
significantly following EPO withdrawal. Erythrocyte deformability, and
granulocyte aggregation did not change. There was no effect of route of
EPO administration (subcutaneous or intravenous) or EPO dose on any
of these parameters. The iron dextran treated patients had increased
platelet aggregation and tissue plasminogen activator antigen in associ-
ation with a smaller increment in hemoglobin. In conclusion, EPO may
be associated with changes in blood coagulation and fibrinolysis: (a)
transiently, during the initial months of therapy, (b) after correction of
anemia, and (c) following EPO withdrawal, Some of these changes
could influence the risk of thrombosis during EPO therapy.
Recombinant human erythropoietin (EPO) is a highly effec-
tive treatment for anemia in chronic renal failure. Its use may,
however, be associated with the development of hypertension,
seizures and thrombotic events [1, 2]. Although a rise in
hematocrit increases blood viscosity, reverses hypoxic vasodi-
lation and thus increases peripheral vascular resistance, many
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of the unwanted side effects of EPO seem to occur during the
earlier months of therapy, often before a significant increment
in hematocrit has taken place [3], and appear to be unrelated to
its rate of change [2]. A placebo controlled Canadian study [I]
demonstrated an increased frequency of adverse events at
higher EPO doses, which, in combination with in vitro studies
showing a dose-dependent vasopressor effect of EPO [4], raises
the additional possibility of a more direct causal relationship
between EPO and some of its unwanted effects. Certainly
seizures have been described in the absence of hypertension [2]
and the more anemic or anephric patients seem to be at greatest
risk [5]. Larger studies of EPO used subcutaneously appear to
have a lower incidence of side effects [6], which would concur
with the in vitro work since supraphysiological EPO levels only
tend to occur immediately following intravenous injections [7].
Microcirculatory factors could also have a role in the devel-
opment of thrombotic events and seizures during EPO therapy.
Several groups have demonstrated improved platelet function
with EPO [8—12], the patients' platelets becoming more spon-
taneously reactive in vitro by comparison with those from
normal individuals [8]. In addition, transient changes in protein
C'3 and thrombin-antithrombin III complex (TAT III) [14]
during the earlier months of therapy have been described, and
may represent markers of a prothrombotic tendency during that
period. Other studies have shown changes in Factor VIII
related activities, fibrinogen, and markers of fibrinolysis in
association with the increase in hematocrit [15, 16]. No study to
date, however, has investigated in detail the interactions be-
tween red cells, white cells and platelets, and markers of
hemostasis and fibrinolysis in patients receiving both subcuta-
neous and intravenous EPO. In addition, when EPO is with-
drawn, hemoglobin falls briskly [17]. The effect of a rapid loss
of red cells in a system attuned to a higher hemoglobin merits
further study since seizures and thrombotic events have also
been described following EPO withdrawal [2, 171.
In this study, assessment of blood coagulation and fibrinoly-
sis was performed monthly on a group of hemodialysis patients
undergoing two phases of EPO therapy separated by an EPO-
free washout period. Ten hemodialysis patients with intrinsi-
cally high hemoglobins, four of whom had previously been
monitored during treatment with iron dextran, were also stud-
ied for comparison.
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Methods
Patients
Twenty-one hemodialysis patients, median age 55 (range 20
to 78) years, ten male, eleven female, with anemia solely due to
renal failure (hemoglobin < 8.5 g/dl), were studied. All patients
were receiving thrice weekly hemodialysis for 12 to 15 hr/week,
using flat-plate cuprophan membranes (Gambro Lundia, Gam-
bro AB, Lund, Sweden), and had been on renal replacement
therapy for between one and twelve years (median 4 years).
Their underlying causes of renal failure were: chronic glomer-
ulonephritis (5), chronic pyelonephritis (5), diabetes mellitus
(3), unknown (3), polycystic kidneys (2), renal tuberculosis (1),
analgesic nephropathy (1), and renovascular disease (1). No
patient suffered from aluminium intoxication (serum level < 1.0
jsmol/liter and negative desferoxamine test), B12 or folate
deficiency, or had severe hyperparathyroidism (parathyroid
hormone level and bone biopsy). No patient was taking any
medication known to influence blood coagulation or EPO
response. Seven patients were controlled hypertensives, one
smoked, and seven had previously undergone parathyroidec-
tomy.
For comparison with the EPO-treated patients, ten hemodi-
alysis patients, median age 54 (range 31 to 61) years, nine male,
one female, stable on dialysis for between six months and
thirteen years (median four years), with intrinsically high he-
moglobins (> 9.0 g/dl) were also studied (controls). Their
underlying causes of renal failure were: hypertensive nephrop-
athy (4), chronic glomerulonephritis (2), polycystic kidneys (2),
chronic pyelonephritis (1), and unknown (1). In the preceding
year, four of these patients were tested monthly during induc-
tion of a moderate increment in hematocrit by monthly iron
dextran infusions (500 mg Imferon, Fisons Ltd., UK). Five of
these patients were receiving antihypertensive therapy, four
smoked, and five had undergone parathyroidectomy.
Erythropoietin therapy has been shown to be effective in
hemodialysis patients with multiple myeloma [18]. Since these
patients may be considered to be at increased risk of thrombosis
due to the paraproteinemia, monthly coagulation tests were
performed on two hemodialysis patients (female 45 years, male
53 years) with myeloma who were receiving EPO therapy. In
addition, tests were also performed on an epileptic hemodialy-
sis patient (male 21 years) receiving EPO on a named-patient
basis.
Methods
After a four week transfusion-free period, during which
baseline tests were performed, the patients were commenced
on 120 lU/kg/week EPO (Epoetin beta, Boehringer Mannheim,
UK Pharmaceuticals Ltd.) administered in three divided doses
post-dialysis. They were randomly assigned to receive their
EPO either subcutaneously or intravenously. After six weeks,
the dose was reviewed at fortnightly intervals, and altered as
required to achieve a target hemoglobin of 10 to 12 g/dl (first
correction phase). After maintenance of target hemoglobin for a
period of eight weeks (first maintenance phase), EPO was
withdrawn, and hemoglobin allowed to fall back to stabilize
within 0.5 g/dl of the pre-treatment level (washout phase). The
patients then received a second course of EPO therapy, again
commencing at a dose of 120 lU/kg/week for the first six weeks,
but administered using the alternative route of administration
from the first phase of treatment (second correction and main-
tenance phases).
Pre-dialysis blood pressure, post-dialysis body weight, and
heparin requirement during dialysis were recorded at every
dialysis session. Full blood counts were measured weekly, and
urea and electrolytes and liver function tests fortnightly using
automated counters. Ferritin levels were measured monthly by
radioimmunoas say.
Assays of blood coagulation were performed monthly on
venous blood taken by free flow through a 19G butterfly needle
at 8:00 a.m. just prior to a hemodialysis session. The samples
were tested as follows:
A. Blood anticoagulated with 3.8% trisodium citrate (1 part
citrate, 9 parts blood); 15 ml.
(1.) Platelet aggregation. This was measured using a whole
blood technique [10]. Platelet aggregation was quantified from
the fall in the number of single platelets counted after sponta-
neous (gentle rotation (30 rpm) at 37°C for six minutes) and
induced (collagen 1 gIml, and ADP 1 M) aggregation, using an
Ultra-Flo 100 Whole Blood Platelet Counter (Clay Adams,
UK).
(2.) Factor VIII von Willebrand factor antigen (Fy11-
IvWFAg). FVIIIvWFAg is part of the factor VIII complex
involved in platelet adhesion. It was measured using an en-
zyme-linked immunosorbent assay (ELISA) kit (Dako Ltd.,
UK).
(3.) Fibrinogen. This is the precursor of fibrin, and its level in
plasma is one of the determinants of blood viscosity and the
extent of fibrin deposition. Fibrinogen was measured using a
nephelometric centrifugal analyzer (Automated Coagulation
Laboratory, Instrumentation Laboratories Ltd., Italy).
(4.) Fibrinolysis. Tissue plasminogen activator (tPA) released
from endothelium activates plasminogen, the precursor of plas-
mm. Plasmin then digests fibrin. When cross linked fibrin is
subjected to the action of plasmin, D-dimer is produced.
Plasminogen activator inhibitor (PA!) is an endothelium prod-
uct which inhibits fibrinolysis. Activated protein C, produced
by the liver, stimulates fibrinolysis via endothelial release of
plasminogen activator, and by degrading PAl. It also inhibits
factors V and VIII in the coagulation cascade. These factors
were measured by ELISA using commercially available kits
(Protein C, tPA, PAT, Kabivitrum Ltd., UK; D-dimer, Diagnos-
tica Stago, France).
(5.) Prostacyclin stimulating factor (PGI2SF). The release of
endothelial prostacyclin, which vasodilates and inhibits platelet
aggregation, is controlled by plasma PGI2SF. This was mea-
sured using a bioassay system [19]. Plasma was passed through
an umbilical artery which had previously been depleted of
prostacyclin by repeated washings. The PGI2SF in the test
plasma stimulated further prostacyclin production which was
measured by the ability of the supernatant to inhibit platelet
aggregation (maximum amplitude and rate) in platelet rich
plasma.
(6.) Thrombin-antithrombin III complex (TAT III). The for-
mation of a complex between thrombin generated by the
coagulation cascade and antithrombin III, an alpha-2 globulin,
is an inhibitory mechanism for controlling hemostasis. Elevated
levels of TAT III occur in association with thrombotic disorders
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[20]. This was measured using an ELISA technique (Behring,
Germany).
B. Blood anticoagulated with lithium heparin (15 lU/mi); 10
ml.
(1.) Erythrocyte deformability. After filtration through leuko-
cyte removal filters (Imugard, Terumo, Japan), the remaining
red cells were then resuspended in phosphate buffered saline at
5% hematocrit, and filtered through a 5 jim polycarbonate
membrane (Nucleopore, USA) using the technique of Saniabadi
et al [21]. The mean filtration pressure over the first ten seconds
of filtration at a flow rate of 1.5 mllmin was recorded, and
expressed as the initial steady-state relative filtration pressure
(IRFP). This value, a ratio by comparison with buffer, increases
with reduced deformability.
C. Blood anticoagulated with sodium heparin (10 lU/mi); 5
ml.
(1.) Granulocyte aggregation. This was measured in whole
blood using the method of Fisher et a! [22]. Granulocyte
aggregation was determined from the fall in single granulocyte
count after induction of aggregation by the synthetic aggregat-
ing agent N-formyl-methionyl-leucyl-phenylalanine (fMLP,
Sigma, UK).
For platelet and granulocyte aggregation tests, where stan-
dard reference ranges were not available, studies were also
performed in non-uremic normal individuals (normals) for com-
parison with the dialysis patients.
Statistics
Many of the measured variables could not be assumed to
have normal distributions, hence results are expressed as
medians, interquartiles (graphs), and ranges (text). Analysis of
variance, and Wilcoxon Rank Sum Tests for matched-paired
data were used to test for changes in coagulation factors in
patients receiving EPO, and Mann Whitney U tests to compare
EPO-treated patients with controls. A crossover trials analysis
[23] was used to compare the effect of route of EPO adminis-
tration on those factors measured during both treatment phases
(platelet aggregation, tPA, PAl, D-dimer, PGI2SF, and TAT III)
and Mann Whitney U tests for those factors only measured
during the first treatment phase (FVIIIvWFAg, fibrinogen,
protein C, granulocyte aggregation, and erythrocyte deform-
ability).
Results
All 21 patients entered into the study reached target hemo-
globin during the first phase of EPO therapy [pre-EPO hemo-
globin: 6.9 (5.3 to 8.1) g/dl; first maintenance phase hemoglobin:
10.6(9.0 to 13.3) gldl], and 16 patients completed the study [end
of washout phase hemoglobin (N = 17): 6.8 (4.8 to 8.3) gIdl;
second maintenance phase hemoglobin (N 16): 10.5 (9.6 to
12.7) gIdl, Fig. 1]. The control patients had a hemoglobin
concentration of 11.0(9.1 to 12.4) g/dl. The durations of the first
and second correction phases were 140 (56 to 307) days and 84
(55 to 161) days, respectively, and following EPO withdrawal,
hemoglobin decreased to pre-EPO levels over a period of 56 (21
to 127) days. Two patients did not complete the first mainte-
nance phase due to renal transplantation. In addition, one
patient died from a myocardial infarction during the washout
phase, and another patient was switched to peritoneal dialysis
at the end of the washout phase. A fifth patient completed the
first maintenance phase, but was not withdrawn from EPO.
Hence, 11 patients received EPO intravenously and 10 subcu-
taneously during the first treatment phase, and nine intrave-
nously and seven subcutaneously during the second treatment
phase.
Analysis of the 16 patients who completed the crossover
study showed that route of EPO administration had no signifi-
cant effect on hemoglobin and reticulocyte responses, plasma
biochemistry and liver function tests, EPO dose requirement,
and the incidence of hypertension. These results have been
analyzed and presented elsewhere (data submitted for publica-
tion).
Coagulation studies
Platelet aggregation. There was no significant change in
platelet count throughout the study period [pre-EPO platelet
count: 221 (94 to 337) x l09/liter; first maintenance phase
platelet count: 205 (117 to 293) x 109/liter; end of washout phase
*
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Fig. 1. Changes in hemoglobin (gidi) duringP 1 2 3 4 Ml eW 1 2 3 4 M2 HC EPO therapy. Abbreviations are: P, pre-EPO;
Ml/2, maintenance phases; eW, end of1st Phase EPO 2nd Phase EPO washout phase; HC, hemodialysis controls.
months months * P < 0.01 vs. pre-EPO.
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platelet count: 232 (138 to 397) x lo9fliter; second maintenance
phase platelet count: 201 (86 to 293) x 109/liter; P = 0.28].
Spontaneous platelet aggregation increased significantly dur-
ing EPO therapy to levels which were higher than in normal
individuals and untreated control patients [pre-EPO (N = 21):
46 (12 to 75) %; first maintenance phase (N = 21): 71(37 to 96)
% (P = 0 vs. controls and normals, Fig. 2); controls: 42 (34 to
82) %; normals (N = 23): 37 (10 to 75) %]. When EPO was
withdrawn, spontaneous platelet aggregation decreased in par-
allel with the fall in hemoglobin, but increased again during the
second phase of therapy [end of washout phase (N = 17): 36 (3
to 80) %; second maintenance phase (N = 16): 67 (28 to 92) %;
Fig. 2].
Aggregation induced by I g/ml collagen also increased
during EPO therapy, to a level comparable to the controls
[pre-EPO: 75 (10 to 92) %; first maintenance phase: 82 (54 to 93)
%; controls: 88 (29 to 97) %; normals: 72 (18 to 97) %; Fig. 2].
When EPO was withdrawn, collagen-induced aggregation in-
creased further, peaking at the end of the washout phase [end of
washout phase: 94 (22 to 97) %, P = 0 vs. normals; Fig. 2].
During the second treatment phase, collagen-induced aggrega-
tion fell to a level comparable to that observed during the first
maintenance phase [second maintenance phase: 85 (24 to 94) %;
P = 0.08 vs. normals; Fig. 2].
Platelet aggregation induced by 1 jLM ADP also increased
slightly following EPO [pre-EPO: 60 (31 to 92) %; first mainte-
nance phase: 73 (43 to 88) %; controls: 81(51 to 94) %; normals:
73 (39 to 88) %; Fig. 2], but following EPO withdrawal increased
to levels significantly higher than in normals [end of washout
phase: 83 (33 to 89) %; P = 0.017 vs. normals; Fig. 2].
Factor VIII von Willebrand factor antigen
FVIIIvWFAg was elevated pre-EPO, and increased signifi-
cantly during EPO therapy [pre-EPO: 180.3 (104.0 to 373.6) %;
first maintenance phase: 220.0 (82.0 to 392.3) %; Fig. 3]. When
EPO was withdrawn, FVIIIvWFAg increased further [end of
washout phase: 247.0 (161.0 to 384.0) %; P < 0.05 vs. first
maintenance phase; Fig. 3). FVIIIvWFAg in the control pa-
tients [controls: 273.0 (226.0 to 365.0) %] was significantly
higher than the study patients pre-EPO, but was comparable to
them during the first maintenance phase (P = 0.32), and after
EPO withdrawal (P 0.87, Fig. 3).
Fig. 2. Changes in spontaneous collagen-
induced and ADP-induced platelet
aggregation (%) during EPO therapy.
Abbreviation NC is normal controls. Symbols
are: 0.01; 0.02; tP< 0.05.
Fibrinogen
Fibrinogen increased significantly during EPO therapy to
levels comparable to the control patients. This increment was
maintained during the washout phase [pre-EPO: 3.73 (2.41 to
6.38) mg/ml; first maintenance phase: 4.44 (2.69 to 8.80) mg!ml;
end of washout phase: 4.37 (2.89 to 8.93) mglml; controls: 5.03
(2.82 to 6.23) mg/ml; Fig. 4].
Fibrinolysis
Plasminogen activator inhibitor increased during the first
correction phase, whereas tPA did not change (Table 1). The
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Fig. 3. Changes in FVIIIvWFAg (% normal) during EPO therapy, and
levels oIFVIIIvWFAg in 4 patients prior tofistula thrombosis (ET). *
<0.01.
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Thrombin-antithrombin III complex
control patients had higher tPA and PA! levels than the study
patients (Table 1). Protein C showed a transient decrease during
the first correction phase (Fig. 5). In most patients, this de-
crease occurred within the first three months of therapy, and
was unrelated to the change in hemoglobin [pre-EPO: 94 (53 to
169) %; 3 months EPO: 85 (58 to 122) % (P = 0.002 vs.
controls); controls: 106 (74 to 131) %]. Only three of 21 patients,
however, attained levels of less than 60%, which are thought to
predispose to thrombosis [24]. D-dimer was higher than normal
both in the controls and also in the study patients, but did not
change with EPO therapy. A significant increment in D-dimer,
however, occurred during the washout phase, the levels grad-
ually returning to those observed during the first phase of EPO
therapy, during the initial months of the second treatment phase
(Table 1).
Prostacyclin stimulating factor
Prostacyclin stimulating factor decreased transiently but sig-
nificantly during the first correction phase [pre-EPO: 97 (82 to
99) %; 3 months EPO: 87 (73 to 94) (P = 0.025 vs. controls; Fig.
5); first maintenance phase: 91(83 to 99) %; controls: 95 (84 to
98) %]. A similar decrease was not seen during the second
phase of therapy, and there was no change following EPO
withdrawal [end of washout phase: 97 (69 to 108) %, second
maintenance phase: 99 (70 to 123) %, Fig. 5].
Levels of this complex showed a transient and significant
increase during the first treatment phase, which occurred at a
similar time to the changes in protein C and PGI2SF, and was
unrelated to the absolute level of hemoglobin [pre-EPO: 3.8 (2.7
to 17.0) sg/liter; 3 months EPO: 15.9 (5.6 to 60.0) pjg/liter (P
0 vs. controls; Fig. 5); first maintenance phase: 5.2 (1.2 to 21.7)
pg/liter; controls: 3.0 (1.2 to 12.6) pg/liter]. A similar increase
was also observed during the second treatment phase [end of
washout phase: 3.7 (1.6 to 16.3) tWliter; second maintenance
phase: 9.4 (2.7 to 21.4) pg/liter; Fig. 5].
Erythrocyte deformability and granulocyte aggregation
Erythrocyte deformabiity and granulocyte aggregation did
not change during the study period (Table 1). Granulocyte
aggregation was, however, significantly higher in the dialysis
patients by comparison with age-matched normals [pre-EPO: 62
(28 to 86) %; normals (N = 30): 43 (33 to 56) %; P = 0].
Route of EPO administration and EPO dose had no signifi-
cant influence on any of the coagulation parameters measured.
The four patients receiving a six month course of monthly iron
dextran infusions had higher pre-treatment hemoglobins than
the EPO treated patients, and showed a much smaller rise in
hemoglobin (pre-treatment 7.2 g/dl, 8.4 g/dl, 9.1 g/dl, and 9.2
gIdl, to post-treatment 9.1 g/dl, 9.3 g/dl, 11.3 gIdl, and 10.3 g/dl,
respectively). The only changes observed in this group were
increases in spontaneous platelet aggregation (pre-treatment
41%, 27%, 18%, and 92%, to post-treatment 47%, 36%, 75%,
and 91%, respectively), and collagen-induced platelet aggrega-
tion (pre-treatment 22%, 76%, 80%, and 91%, to post-treatment
29%, 92%, 88%, and 97%, respectively), and in tPA (pre-
treatment 98%, 61%, 249%, and 222%, to post-treatment 108%,
131%, 298%, and 321%, respectively). The two patients with
multiple myeloma and the epileptic patient showed similar
coagulation and fibrinolysis changes to the other EPO-treated
patients (results not shown).
Four EPO-treated patients had single episodes of fistula
thrombosis, all during the first treatment phase. In addition, one
patient died from a myocardial infarct following EPO with-
drawal, and another patient developed an ileofemoral thrombo-
sis during the second treatment phase. The epileptic patient was
withdrawn from the study due to seizures at seven months.
Most of these patients had increased platelet aggregation, and in
those patients with fistula thrombosis, the levels of FyI!-
IvWFAg and fibrinogen were high in the monthly coagulation
test performed prior to the adverse event (Fig. 3 and 4, Table 2).
In the epileptic patient, the increments in platelet aggregation
and fibrinogen were particularly large considering his poor
hemoglobin response to EPO (Table 2). This patient also
demonstrated a gradual decrease in tPA during treatment to a
level which was very low (17%) just prior to the adverse event.
Five of the seven patients who were hypertensive pre-EPO
required an increase in antihypertensive therapy, and six nor-
motensive patients became hypertensive requiring treatment.
No specific coagulation parameter measured appeared to sig-
nificantly distinguish the hypertensive patients from those re-
maining normotensive.
In the control group, although tests of coagulation and
fibrinolysis were performed on a single occasion only, during
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Fig. 4. Change in fibrinogen (mg/mi) during EPO therapy, and levels
offibrinogen in 4 patients prior tofistula thrombosis. The normal range
of fibrinogen is 2 to 4 mg/mi. Symbols are: * P < 0.01.
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Table 1. Changes in tissue plasminogen activator antigen, plasminogen activator inhibitor, D-dimer, erythrocyte deformability and granulocyte
aggregation in study patients
Pre-EPO
1st Maintenance
phase (end)
End of
washout
2nd Maintenance
phase (end) Controls
Tissue plasminogen 72 74 129 100 l42
activator antigen (34—169) (11—251) (29—263) (11—321) (82—298)
% normal
Plasminogen 5.5 109b 10.0 6.5 15.5a
activator inhibitor AU/mi (1.0—23.4) (2.2—25.8) (1.0—96.,2) (0.9—12.4) (7.6—32.4)
D-dimer 719 718 916 670 527
ng/mi (247—1000) (111—1239) (258—1547) (245—2184) (200—1000)
Granulocyte 62 57 62 ND 52
aggregation % (28—86) (27—69) (40—78) (4 1—59)
Erythrocyte 1.35 1.36 1.36 ND 1.34
deformability (IRFP) (1.27—1.54) (1.25—1.50) (1.27—1.42) (1.27—1.41)
a P < 0.01, 'P < 0.02 vs. pre-EPO
Normal ranges are: plasminogen activator inhibitor, 6.7(2.0 to 40.0) AU/mI, D-dimer: <400 ng/mI; erythrocyte deformability, 1.11 to 1.38. ND
is not done.
Discussion
This study has demonstrated changes in blood coagulation
and fibrinolysis in hemodialysis patients during treatment with
EPO and following EPO withdrawal, which could favor a
predisposition to thrombosis. Many of the measured variables
tended towards those levels observed in untreated hemodialysis
patients with long-standing intrinsically higher hemoglobins.
Renal dialysis patients as a group have increased mortality from
vascular causes [25], in association with histological evidence
of an abnormal vasculature [26]. It is therefore tempting to
speculate that the increased hematocnt induced by EPO, with
its associated effects on blood viscosity, blood coagulation and
peripheral vascular resistance, in the presence of such abnor-
mal blood vessels, may further exacerbate morbidity and mor-
tality from vascular causes. Certainly, similar side effects are
not observed in non-uremic patients with normal blood vessels
who are treated with EPO for autologous pre-operative blood
transfusion [27].
In this study as in others [8—12], EPO therapy was associated
with changes in platelet function in vitro. However, unlike most
other studies, by using a whole blood technique, and thus
allowing physiological interactions between platelets and other
blood cells to occur, we were also able to show that correction
of anemia produced enhanced spontaneous and collagen-in-
T duced platelet aggregation in the dialysis patients by compari-
son with normals. In keeping with our findings, Gordge eta! [28]
previously demonstrated the importance of the presence of red
cells when investigating platelet function in uraemic patients in
vitro.
Red cells may influence platelet interactions by the release of
HC pro-aggregatory substances, in particular ADP, both in the
immediate vicinity of platelet contact as well as into the
surrounding medium [29], and by physically channeling the
platelets towards the endothelial surface [30]. In renal failure
these mechanisms could be enhanced due to the red cells being
less deformable [31] and having shortened lifespans [32], with
increased membrane fragility, hemolysis, and presumably in-
creased release of platelet activating substances. Physical
mechanisms, that is, contact-interaction between red cells and
platelets with the release of endogenous red cell ADP at the site
of platelet contact, are probably the most important factors
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Fig. 5. Changes in TAT III (jsg/liter), PGI2SF (% normal) and protein
C (% normal) during EPO therapy. The normal range of TAT III is 1.0
to 4.1 tg/liter. * P <0.01; * P <0.02; t P <0.05.
the period over which the EPO-treated patients were studied,
two patients in this group experienced fistula thrombosis, and a
further patient died following a myocardial infarct.
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Table 2. Adverse events in study patients
Patient
No. Event
EPO dose
lU/kg/week Route
Phase/time
(days)
Hemoglobin
g/dl
FVIIIvWFAg
%
Fibrinogen
mg/mi
Spontaneous
platelet
aggregation %
Collagen
induced platelet
aggregation
1. Clotted 225 s.c. 1 (145) 9.7 273 (208) 5.57 (4.94) 73 (46) 81(88)
fistula
2. Clotted 180 s.c. 1(68) 9.1 527.2 (174) 5.59 (6.32) 66 (38) 81(72)
fistula
3. Clotted 250 i.v. 1(361) 10.9 317 (167.3) 3.48 (2.75) 19 (21) 46 (33)
fistula
4. Clotted 225 i.v. 1 (64) 8.3 357.3 (295) 7.15 (5.05) 86 (29) 94 (63)
fistula
5. Seizurea 570 i.v. 1(196) 7.2 228 (219.6) 5,15 (2.48) 65 (18) 90 (56)
6. Myocardial 0 — W 10.5 286 (155) 4.09 (3.29) 93 (48) 95 (88)
infarction
7. Ileofemoral 370 i.v. 2 (126) 9.6 ND (239) ND (5.03) 57 (30) 85 (95)
thrombosis
Numbers in brackets give pre-EPO values. Abbreviations are: W, washout phase; ND, not done.
a Epileptic patient
governing spontaneous platelet aggregation since this most
closely paralleled the changes in red cell number during the
study period.
Our observation of increased platelet aggregability to colla-
gen and ADP following EPO withdrawal could be due to the
release of prothrombotic substances into the surrounding me-
dium from the relatively larger proportion of older red cells
succumbing to the uremic process. Indeed, the fall in hemoglo-
bin was rapid following EPO withdrawal, and occurred in a
vascular system which would have adjusted hemodynaniically
(that is, more vasoconstricted) to a higher hematocrit. Since,
however, platelet hyperaggregability in vitro has been associ-
ated with thrombosis in vivo [33], these observations might
caution the withdrawal of EPO in clinical practice, such as prior
to vascular access operations, and would argue the case for
prophylactic aspirin therapy in those patients receiving EPO
who are clinically considered to be at risk of thrombosis.
Factor VIII von Willebrand factor antigen is necessary for
platelet-platelet, and platelet-endothelial interactions [34]. It is
synthesized and stored by the vascular endothelium, and is
released in the presence of endothelial damage. For this reason,
in other disease states, it has been used as a marker for
monitoring the progression of vasculitis [35] which has certain
features (for example, chronic inflammatory cell infiltration) in
common with uremic vasculopathy. In renal failure, Fy11-
IvWFAg is significantly elevated by comparison with normal
individuals, but its structural form may be altered such that less
is present in the form of the larger multimers thought necessary
for effective interactions with platelets [36]. There is, however,
no evidence to suggest that the multimeric structure is altered
during EPO therapy [9]. Since our control patients with long-
standing high hemoglobins had the highest FVIIIvWFAg, it is
possible that this elevation of FVIIIvWFAg could represent
endothelial damage consequent upon a higher red cell mass in a
more vasoconstricted but abnormally structured vasculature.
The increase in FVIIIvWFAg following EPO withdrawal is also
probably endothelium derived since it is unlikely that mega-
karyocytes, the other source of FVIIIvWFAg, would increase
in the absence of EPO [37], and platelet-derived FVIIIvWFAg
is usually redistributed rather than released during the aggrega-
tion process [38]. This effect cannot, however, be due to the
physical effects of red cell mass. It is possible that it may be
mediated by enhanced platelet activation following EPO with-
drawal, which could cause endothelial damage thus perpetuat-
ing FVIIIvWFAg release.
Fibrinogen is an important determinant of plasma viscosity.
In addition, high levels of fibrinogen have been associated with
enhanced platelet aggregation, and are a risk factor for mortal-
ity from myocardial infarction and stroke [39]. Koppensteiner
et al [40] noted increased baseline fibrinogen levels in those
patients who later developed vascular access thrombosis during
EPO therapy. Certainly, in our study fibrinogen levels were
often high when measured just prior to a thrombotic event. The
overall trend, though, was for fibrinogen to increase with EPO
towards those levels observed in the control patients. Unex-
pectedly it did not decrease again when EPO was withdrawn.
The association of a high hematocrit with high fibrinogen levels,
both in EPO-treated and in control patients, is perhaps an
additional cardiovascular risk factor when relatively normal
hemoglobin levels are maintained in these patient groups.
Plasminogen activator inhibitor increased during the first
correction phase, but remained within the normal range.
D-dimer, however, increased significantly following EPO with-
drawal. D-dimer is a useful marker of fibrinolysis in renal
disease since its level is not influenced by impaired renal
clearance [41]. EPO withdrawal therefore particularly appeared
to be associated with enhanced fibrinolytic activity. Interest-
ingly, both patients (at all time points during the study period)
and controls had higher than normal D-dimer levels. Such
enhanced fibrinolysis not only reflects the activation of coagu-
lation (since the two processes are closely interlinked in vivo),
but may also serve to protect against significant thrombus
formation.
The observation of transient changes in protein C, PGI2SF
and TAT III occurring at approximately the same time during
the initial months of the first EPO treatment phase was not
expected since they took place in the majority of patients prior
to reaching target hemoglobin. Macdougall et al [13] also
demonstrated a similar fall in protein C during this initial EPO
treatment period. Although in our study the fall in protein C was
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not clinically significant in most patients, the rise in TAT III
was. Similarly, plasma from uremic patients has been shown to
have an increased capacity to stimulate endothelial prostacyclin
production [42], and hence our observed decrease in PGI2SF
may also be of clinical relevance. During the second treatment
phase protein C was not measured, and the only transient
change occurred in TAT III at a time and hemoglobin concen-
tration which were not significantly different from the first
treatment phase. It is possible that, due to any potential
carryover effect from the washout phase and/or the shorter
duration of the second treatment phase, changes in PGI2SF and
PAl were missed during this period. Interestingly, clinical trials
of EPO have shown an increased incidence of side effects, in
particular seizures, during the first few months of treatment [2,
3], the incidence falling with time despite continuation of EPO
therapy and maintenance of a higher hemoglobin level. This
would suggest that there is an initial "at risk" period, unrelated
to either EPO dose or absolute hemoglobin concentration, and
our findings could reflect some of the changes which may be
occurring at this time.
Granulocyte count and activity have been linked to athero-
sclerotic disease in experimental, epidemiological and clinical
studies [43]. Activated granulocytes release free radicals which
damage endothelial cells, enhance platelet aggregation, and
reduce erythrocyte deformability. Although the granulocytes
from the dialysis patients were hyperaggregable, this was not
increased by EPO, and granulocyte counts remained within the
normal range. Additionally, erythrocyte deformability, which
might have been expected to decrease during EPO therapy
owing to a greater proportion of red cells being the relatively
'harder' reticulocytes, did not change, perhaps because reticu-
locytes generally form only a small percentage of the total red
cell count.
The four iron-deficient hemodialysis patients who were fol-
lowed during the course of iron dextran therapy had increases
in platelet aggregation and tPA only, the other factors remaining
essentially unchanged. They did not demonstrate the transient
changes in PGI2SF, TAT III and protein C observed in the EPO
treated patients. These patients, however, had higher pre-
treatment hemoglobins and their increments in hemoglobin
were considerably less than in the study patients. Similarly,
since there was no effect of route of EPO administration or EPO
dosage on any of the variables measured, it is difficult to draw
conclusions from our studies regarding any additional direct
effects of EPO on coagulation other than those incurred indi-
rectly by the rise in hematocrit alone. Other studies have shown
hematocrit-independent changes in platelet aggregation and
subendothelial adhesion in patients receiving EPO [11, 12].
Again, these effects were considered most likely to be due to
either the influence of EPO on megakaryocyte maturation to
produce younger, more active platelets [12], or alternatively,
changes in the levels of potential inhibitory factors consequent
upon improved tissue oxygenation and erythrocyte binding
[11], rather than any direct action of EPO.
The two EPO-treated patients with multiple myeloma did not
appear to be at greater risk of thrombosis, which was not
unexpected, since their paraprotein levels remained below 10
g/liter during the study period. All patients who developed
thrombotic events had increased platelet aggregation. The
pre-event high levels of FVIIIvWFAg in the four patients with
fistula thrombosis could represent vascular damage and thus a
predisposition to the subsequent thrombosis. Three of these
four patients also had high fibrinogen levels and thus the
substrate for clot formation. Interestingly, approximately sim-
ilar rates of fistula thrombosis were seen in the control group
over the same time period. These patients also had high levels
of FVIIIvWFAg and fibrinogen, thus reinforcing the possible
link between a high hematocrit and vascular endothelial damage
in the setting of renal failure.
In conclusion, hemodialysis patients have increased morbid-
ity and mortality from vascular causes, and yet paradoxically
have a bleeding tendency particularly in the presence of ane-
mia. Erythropoietin therapy improves this bleeding tendency
primarily by the influence of red cells on platelet function. The
increased red cell mass may, however, perpetuate vascular
damage, and long-term follow-up of these patients will ulti-
mately determine if morbidity and mortality increases. In this
study, route of EPO administration and EPO dosage did not
appear to influence coagulation changes, and conclusive evi-
dence of a direct effect of EPO was lacking. EPO withdrawal
may potentially increase the risk of thrombosis and perhaps
should be avoided. Prophylactic use of aspirin could be helpful
in those patients considered to be at greatest risk.
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